Kanseri y'ibihaha ikomeje kuba intandaro y'impfu ziterwa na kanseri ku isi hose, hamwe naKanseri y'ibihaha itari ntoya (NSCLC) igera kuri 85% by'indwara zose.Mu myaka ibarirwa muri za mirongo, kuvura NSCLC yateye imbere byashingiraga cyane cyane kuri chimiotherapie, igikoresho kidahwitse gitanga umusaruro muke nuburozi bukomeye.
Guhindura uburyo bwo kuvura byatangiranye no kuvumbura “mutation mutation” - ihinduka ryihariye rya genetike ritera gukura kwikibyimba. Ibi byatumye habaho ubuvuzi bugamije, bukora nka misile ziyobowe neza, zangiza burundu kanseri ya kanseri mu gihe zirinda izifite ubuzima bwiza. Nyamara, intsinzi yubuvuzi bwimpinduramatwara ishingiye rwose kubizamini bya geneti byukuri kandi byizewe kugirango hamenyekane intego nziza kumurwayi ukwiye.
Ibinyabuzima byingenzi: EGFR, ALK, ROS1, na KRAS
Biyomarkeri enye zihagarara nkinkingi mugupima molekuline ya NSCLC, iyobora ibyemezo byo kuvura umurongo wa mbere:
-EGFR:Imihindagurikire yimikorere igaragara cyane cyane mubanya Aziya, abategarugori, nabatanywa itabi. EGFR tyrosine kinase inhibitor (TKIs) nka Osimertinib yazamuye cyane umusaruro wabarwayi.
-ALK:“Guhindura diyama,” igaragara muri 5-8% by'imanza za NSCLC. ALK fusion-positif abarwayi bakunze kwitabira cyane ALK inhibitor, bakageraho igihe kirekire.
-ROS1:Kugabana ibintu bisa na ALK, iyi "mabuye y'agaciro" iboneka muri 1-2% by'abarwayi ba NSCLC. Uburyo bwiza bwo kuvura burahari, butuma bumenya neza.
-KRAS:Amateka afatwa nk "adakemurwa," ihinduka rya KRAS rirasanzwe. Iyemezwa rya vuba rya inhibitori ya KRAS G12C ryahinduye iyi biomarker kuva ku kimenyetso cyamenyekanye ihinduka intego igaragara, ihindura uburyo bwo kwita kuri iyi sisitemu yumurwayi.
MMT Portfolio: Yashizweho Kubyiringiro byo Gusuzuma
Kugira ngo byihutirwa gukenera kumenya neza ibimenyetso bya biomarker, MMT itanga portfolio ya CE-IVD yaranze ibikoresho nyabyo bya PCR byerekana igihe nyacyo, buri kimwe cyakozwe nubuhanga bugezweho kugirango hamenyekane icyizere cyo gusuzuma.
1. Igikoresho cyo kumenya ihinduka rya EGFR
-Ikoranabuhanga rya ARMS ryazamuye:Abazamura umutungo bongera ihinduka ryihariye rya mutation.
-Gukungahaza Enzymatique:Kubuza endonuclease gusya ubwoko bwimiterere yimiterere yimiterere yinyamanswa, bikungahaza mutant bikurikirana kandi byongera ibisubizo.
-Guhagarika ubushyuhe:Intambwe yihariye yubushyuhe igabanya priming idasanzwe, ikomeza kugabanya ubwoko bwimiterere yinyamanswa.
-Inyungu z'ingenzi:Ntagereranywa sensibilité hasi kugeza1%mutant allele inshuro nyinshi, ubunyangamugayo buhebuje hamwe nigenzura ryimbere hamwe na enzyme ya UNG, nigihe cyihuta cyo guhinduka hafiIminota 120.
- Bihujwe nabyombi hamwe na biopsy byamazi.
2.MMT EML4-ALK Igikoresho cyo Kumenya
- Ubushishozi bukabije:Kumenya neza ihinduka ryimiterere ihindagurika hamwe ntarengwa yo kumenya kopi 20 / reaction.
-Ubwiza buhebuje:Harimo ibipimo byimbere mugucunga inzira hamwe na enzyme ya UNG kugirango wirinde kwanduza karryover, wirinde neza ibyiza nibibi.
-Byoroshye & Byihuta:Ibiranga imikorere yoroheje, ifunze-tube yarangiye muminota igera kuri 120.
-Guhuza ibikoresho:Ihuza nibikoresho bitandukanye bisanzwe-bisanzwe bya PCR, bitanga ibintu byoroshye muri laboratoire.
3.MMT ROS1 Igikoresho cyo Kumenya
Ubushishozi bukabije:Yerekana imikorere idasanzwe mugushakisha byimazeyo nka kopi 20 / reaction yintego zo guhuza.
Ubwiza buhebuje:Gukoresha igenzura ryimbere ryimbere hamwe na enzyme ya UNG itanga ubwizerwe bwibisubizo byose, bigabanya ingaruka zo gutanga amakosa.
Byoroshye & Byihuta:Nka sisitemu ifunze-sisitemu, ntabwo bisaba intambwe igoye nyuma yo gukwirakwizwa. Intego kandi yizewe iboneka muminota igera kuri 120.
Guhuza ibikoresho:Yashizweho kugirango ihuze cyane hamwe nurwego rwimashini nyamukuru ya PCR, yorohereza kwinjiza byoroshye muri laboratoire ikora.
4.MMT KRAS Igikoresho cyo Gutahura
- Ikoranabuhanga rya ARMS ryongerewe imbaraga, rikomezwa na Enzymatic Enrichment hamwe no guhagarika ubushyuhe.
- Gukungahaza Enzymatique:Koresha kubuza endonuclease kugirango uhitemo neza igogora ryubwoko bwimiterere yinyamanswa, bityo bikungahaye kuri mutant bikurikirana kandi bizamura cyane gukemura.
-Guhagarika ubushyuhe:Itangiza intambwe yihariye yubushyuhe kugirango itere kudahuza hagati ya mutant yihariye ya primers nubwoko bwinyamanswa, bikomeza kugabanya imiterere no kunoza umwihariko.
- Ubushishozi bukabije:Kugera kuri sensibilité ya 1% kuri mutant alleles, ukemeza kumenya ihinduka ryinshi ryimiterere.
-Ubwiza buhebuje:Kwinjiza imbere imbere hamwe na enzyme ya UNG irinda ibisubizo byiza nibibi.
-Akanama gashinzwe:Byashyizweho neza kugirango byorohereze kumenya ihinduka umunani ritandukanye rya KRAS ihindagurika ryibice bibiri gusa.
- Byoroshye & Byihuta:Tanga ibisubizo bifatika kandi byizewe muminota igera kuri 120.
- Guhuza ibikoresho:Ihuza neza nibikoresho bitandukanye bya PCR, itanga ibintu byinshi kuri laboratoire.
Kuki uhitamo igisubizo cya MMT NSCLC?
Byuzuye: Suite yuzuye kubinyabuzima bine bya NSCLC bikomeye.
Ikoranabuhanga risumba ayandi: Gutezimbere umutungo (Enzymatic Enrichment, Guhagarika Ubushyuhe) byemeza umwihariko no kumva neza aho bifite akamaro kanini.
Byihuse & Bikora: Uniform ~ iminota 120 protocole kuri portfolio yihutisha igihe-cyo-kuvura.
Byoroshye & Byoroshye: Bihujwe nurwego runini rwicyitegererezo hamwe nibikoresho nyamukuru bya PCR, kugabanya inzitizi zishyirwa mubikorwa.
Umwanzuro
Mubihe bya oncologiya isobanutse, kwisuzumisha molekulari ni compas iyobora inzira yo kuvura. Ibikoresho bya MMT byateye imbere byongerera imbaraga abaganga gushushanya neza imiterere yimiterere yimiterere ya NSCLC yumurwayi, bikingura ubushobozi bwo kurokora ubuzima bwo kuvura.
Contact to learn more: marketing@mmtest.com
Igihe cyo kohereza: Ukwakira-14-2025